Non-Hodgkin's lymphoma: Long-term survivors and adverse effects

Annals of Oncology

Volumn 11, Issue SUPPL. 3, 2000, Pages 123-128

  Epelbaum, R ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ACUTE NONLYMPHOCYTIC LEUKEMIA; BRAIN LYMPHOMA; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CONFERENCE PAPER; DRUG INDUCED DISEASE; HUMAN; INFERTILITY; LUNG TOXICITY; LYMPHOMA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SECOND CANCER; SOLID TUMOR; TREATMENT OUTCOME;

EID: 0033770916     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/11.suppl_3.123     Document Type: Conference Paper

References (64)

1. A predictive model for aggressive non-Hodgkin's lymphoma
2. High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin's lymphoma
3. Long-term toxicity of the treatment of Hodgkin's disease
4. Adverse effects of treatment: Second cancers
5. Second malignancies in non-Hodgkin's lymphoma
6. Late effects in long-term survivors of high-grade non-Hodgkin's lymphoma
7. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphoma. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents
8. Second cancer following lymphatic and hematopoietic cancers in Denmark, 1943-80
9. Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas
10. Second malignant neoplasms in patients with non-Hodgkin's lymphoma
11. Second malignancies following treatment in non-Hodgkin's lymphoma
12. Second cancers among long-term survivors of non-Hodgkin's lymphoma
13. Risk of leukemia following treatment for non-Hodgkin's lymphoma
14. Secondary acute myeloid leukemia following treatment with VP16 containing regimens for non-Hodgkin's lymphoma
15. Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin's lymphoma
16. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma
17. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation
18. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma
19. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies
20. Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy
21. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma
22. Second cancer following lymphatic and hematopoietic cancers in Connecticut, 1935-82
23. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma
24. Lung cancer in chronic leukemia and lymphoma
25. Lung cancer as a complication of prolonged survival in patients with lymphoma
26. Second lung adenocarcinoma after combination chemotherapy in two patients with primary non-Hodgkin's lymphoma
27. Lung cancer following Hodgkin's disease: A case-control study
28. High incidence of other neoplasms in patients with low-grade gastric MALT lymphoma
29. Incidence of second neoplasms in patients with MALT lymphoma: No increase in risk above the background population
30. Semen preservation and gonadal toxicity in the treatment of non-Hodgkin's lymphoma. Experience at the Gustave-Roussy Institute from 1980 to 1993
31. Sperm quality in Hodgkin's disease versus non-Hodgkin's lymphoma
32. A programme of semen cryopreservation for patients with malignant disease in a tertiary infertility center: Lessons from 8 years experience
33. Gonadal toxicity after combination chemotherapy of Hodgkin's disease. Comparative studies of MOPP vs. ABVD
34. Male fertility after VAPEC-B chemotherapy for Hodgkin' disease and non-Hodgkin's lymphoma
35. Prognostic factors, late relapse and outcome of patients with aggressive malignant lymphoma: Long term results of LNH-80 protocol
36. Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma
37. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma
38. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas
39. Early high dose chemotherapy intensification with autologous bone marrow transplantation in lymphoma associated with retention of fertility and normal pregnancies in females. Scotland and Newcastle Lymphoma Group, UK
40. Pregnancy after autologous bone marrow transplantation for malignant lymphomas
41. Thyroid, pulmonary, and cardiac sequelae after treatment for Hodgkin's disease
42. QT dispertion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma
43. Late pulmonary toxicity after treatment for Hodgkin's disease
44. Effect of treatment for Hodgkin's disease on pulmonary function: Results of a prospective study
45. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease
46. Assessment of cardiac and pulmonary function in adult patients with Hodgkin's disease treated with ABVD or MOPP/ABD plus adjuvant low-dose mediastinal irradiation
47. Fatal pulmonary fibrosis from low-dose bleomycin therapy
48. Severe lung toxicity with a weekly low dose chemotherapy regimen in patients with non-Hodgkin's lymphoma
49. Pulmonary toxicity in patients with non-Hodgkin's lymphoma treated with bleomycin-containing combination chemotherapy
50. CODBLAM IV chemotherapy for large cell lymphoma: Sequential use of infusional vincristine and bleomycin and 'high dose' consolidation
51. COPBLAM III: Infusional combination chemotherapy for diffuse large-cell lymphoma
52. Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens
53. Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma
54. Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation
55. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation
56. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma
57. High-dose methotrexate for treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series
58. Primary CNS lymphoma: Treatment with combined chemotherapy and radiotherapy
59. Neurologic sequelae of treatment of primary CNS lymphomas
60. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients
61. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma
62. Neuropsychological assessment outcome of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy
63. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas
64. Neurological illness following treatment with fludarabine